Komposition:
Wird bei der Behandlung verwendet:
Medizinisch geprüft von Fedorchenko Olga Valeryevna, Apotheke Zuletzt aktualisiert am 12.03.2022
Achtung! Die Informationen auf der Seite sind nur für medizinisches Fachpersonal! Die Informationen werden in öffentlichen Quellen gesammelt und können aussagekräftige Fehler enthalten! Seien Sie vorsichtig und überprüfen Sie alle Informationen auf dieser Seite!
Top 20 Medikamente mit den gleichen Inhaltsstoffen:
Top 20 Medikamente mit dem gleichen Gebrauch:
Tranylcypromin Amdipharm ist zur Behandlung von Major Depression (MDD) bei erwachsenen Patienten indiziert, die auf andere Antidepressiva nicht ausreichend angesprochen haben. Tranylcypromin Amdipharm ist für die Erstbehandlung von MDD aufgrund des Potenzials schwerwiegender Nebenwirkungen und Arzneimittelwechselwirkungen sowie der Notwendigkeit von Ernährungsbeschränkungen nicht indiziert.
Empfohlene Dosierung
Tranylcypromin Amdipharm Tabletten sind zur oralen Anwendung bestimmt. Die empfohlene Dosierung beträgt 30 mg pro Tag (in geteilten Dosen). Wenn Patienten nicht ausreichend ansprechen, erhöhen Sie die Dosierung in Schritten von 10 mg pro Tag alle 1 bis 3 Wochen auf maximal 30 mg zweimal täglich (60 mg pro Tag). Dosierungserhöhungen sollten bei Patienten mit Hypotonie-Risiko (z.geriatrische Patienten).
Wechseln zu oder von anderen Antidepressiva
Umstellung von kontraindizierten Antidepressiva auf Tranylcypromine Amdipharm
Nach Beendigung der Behandlung mit kontraindizierten Antidepressiva sollte vor Beginn der Behandlung mit Tranylcypromin Amdipharm ein Zeitraum von 4 bis 5 Halbwertszeiten des anderen Antidepressivums oder eines aktiven Metaboliten vergehen. Nach Beendigung der Behandlung mit einem MAO-Hemmer-Antidepressivum sollte vor Beginn der Behandlung mit Tranylcypromin Amdipharm ein Zeitraum von mindestens einer Woche oder 4 bis 5 Halbwertszeiten des anderen MAO-Hemmers (je nachdem, welcher Zeitraum länger ist) vergehen, um das Risiko additiver Wirkungen zu verringern.
Wechsel von Tranylcypromine Amdipharm zu anderen MAOs oder kontraindizierten Antidepressiva
Nach Beendigung der Behandlung mit Tranylcypromin Amdipharm sollte mindestens eine Woche vergehen, bevor ein weiterer MAOI (zur Behandlung von MDD) oder andere kontraindizierte Antidepressiva gestartet werden. Informationen zur produktspezifischen Beratung in einem medikamentenfreien Intervall finden Sie in den Verschreibungsinformationen des anschließend verwendeten Arzneimittels.
Behandlung abbrechen
Entzugseffekte, einschließlich Delir, wurden mit abruptem Absetzen der Tranylcypromin Amdipharm-Therapie berichtet. Höhere Tagesdosen und eine längere Verwendungsdauer scheinen mit einem höheren Risiko für Entzugseffekte verbunden zu sein. Erwägen Sie, die Tranylcypromin Amdipharm-Therapie durch langsame, allmähliche Dosisreduktion abzubrechen.
Bildschirm für bipolare Störung und erhöhten Blutdruck vor dem Starten von Tranylcypromine Amdipharm
Vor Beginn der Behandlung mit Tranylcypromin Amdipharm:
- Screening-Patienten auf eine Manie in der Vorgeschichte.
- Blutdruck messen.
Kombination mit bestimmten Drogen
Die gleichzeitige Anwendung von Tranylcypromine Amdipharm oder die schnelle Anwendung mit den Produkten in Tabelle 1 ist kontraindiziert. Eine solche Anwendung kann schwere oder lebensbedrohliche Reaktionen wie hypertensive Krisen oder Serotonin-Syndrom verursachen. Es werden medikamentenfreie Zeiträume zwischen der Verabreichung von Tranylcypromin Amdipharm und kontraindizierten Mitteln empfohlen.
Tabelle 1: Produkte, die mit der Verwendung von Tranylcypromine Amdipharm kontraindiziert sind
Drogenklassen | ||
Nicht selektive H1-Rezeptorantagonisten | ||
Antidepressiva, einschließlich, aber nicht beschränkt auf: | ||
| ||
Amphetamine und Methylphenidate und Derivate | ||
Sympathomimetische Produkte (z.Kalt-, Heuschnupfen- oder gewichtsreduzierende Produkte, die Vasokonstriktoren wie Pseudoephedrin, Phenylephrin und Ephedrin enthalten; oder Nahrungsergänzungsmittel, die Sympathomimetika enthalten) | ||
Triptane | ||
Einzelne Drogen (nicht in den obigen Klassen enthalten) | ||
Buspiron | Levodopa | s-Adenosyl-L-methionin (SAM-e) |
Carbamazepin | Meperidin | Tapentadol |
Cyclobenzaprin | Methyldopa | Tetrabenazin |
Dextromethorphan | Milnacipran | Tryptophan |
Dopamin | Rasagilin | |
Hydroxytryptophan | Reserpin |
Pheochromozytom und Katecholamin-freisetzende Paragangliome
Tranylcypromin Amdipharm ist in Gegenwart eines Pheochromocytoms oder anderer Katecholamin freisetzender Paragangliome kontraindiziert, da solche Tumoren Druckersubstanzen absondern und zu einer hypertensiven Krise führen können.
WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
Suicidal Thoughts And Behaviors In Adolescents And Young Adults
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 2.
Table 2: Risk Differences of the Number of Patients of Suicidal Thoughts and Behavior in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients
Age Range | Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated |
Increases Compared to Placebo | |
<18 years old | 14 additional patients |
18-24 years old | 5 additional patients |
Decreases Compared to Placebo | |
25-64 years old | 1 fewer patient |
≥65 years old | 6 fewer patients |
It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.
Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Tranylcypromine Amdipharm, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
Hypertensive Crisis And Hypertension
Hypertensive Crisis
MAOIs, including Tranylcypromine Amdipharm, have been associated with hypertensive crises caused by the ingestion of foods or beverages with a high concentration of tyramine. In addition, hypertensive reactions and crises may occur with concomitant use of other drugs. Patients with hyperthyroidism may be at greater risk of hypertensive crisis.
Signs, Symptoms, And Complications Of Hypertensive Crisis
In some patients a hypertensive crisis constitutes a hypertensive emergency, which requires immediate attention to prevent serious complications or fatal outcome. These emergencies are characterized by severe hypertension (e.g., with a blood pressure of more than 180/120 mm Hg) and evidence of organ dysfunction. Symptoms may include occipital headache (which may radiate frontally), palpitations, neck stiffness or soreness, nausea or vomiting, sweating (sometimes with fever or cold, clammy skin), dilated pupils, photophobia, shortness of breath, or confusion. Either tachycardia or bradycardia may be present and may be associated with constricting chest pain. Seizures may also occur. Intracranial bleeding, sometimes fatal, has been reported in association with the increase in blood pressure.
Strategies To Reduce The Risk Of Hypertensive Crisis
Instruct patients to avoid foods and beverages with high tyramine content while being treated with Tranylcypromine Amdipharm and for 2 weeks after stopping Tranylcypromine Amdipharm. Careful evaluation of the benefits and risks of Tranylcypromine Amdipharm therapy is necessary in patients with:
- Hypertension or confirmed or suspected cerebrovascular or cardiovascular disorders that constitute an increased risk for complications from severe hypertension, and
- A history of headaches that can mask the occurrence of headaches as prodromal of a hypertensive crisis.
In all patients taking Tranylcypromine Amdipharm, monitor blood pressure closely to detect evidence of increased blood pressure. Full reliance should not be placed on blood pressure readings. The patient should also be observed for other signs and symptoms of hypertensive crisis.
Treatment Of Hypertensive Crisis
Therapy should be interrupted with symptoms that may be prodromal or a manifestation of a hypertensive crisis, such as palpitations or headaches, and patients should be evaluated immediately. Discontinue Tranylcypromine Amdipharm, other drugs, foods or beverages suspected to contribute to the hypertensive crisis immediately.
Patients with severe elevations in blood pressure (e.g., more than 180/120 mm Hg) with evidence of organ dysfunction require immediate blood pressure reduction. Fever should be managed by means of external cooling. However, additional measures to control the causes of hyperthermia (psychomotor agitation, increased neuromuscular activity, persistent seizures) may be required.
Hypertension
Clinically significant increases in blood pressure have also been reported after the administration of MAOIs, including Tranylcypromine Amdipharm, in patients not ingesting tyramine-rich foods or beverages. Assess blood pressure before prescribing Tranylcypromine Amdipharm and closely monitor blood pressure in all patients taking Tranylcypromine Amdipharm.
Serotonin Syndrome
The development of a potentially life-threatening serotonin syndrome has been reported with MAOIs when used concomitantly with other serotonergic drugs. Such drugs include SSRIs, SNRIs, tricyclic antidepressants, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, S-adenosyl-L-methionine (SAM-e), and other MAOIs used to treat nonpsychiatric disorders (such as linezolid or intravenous methylene blue).
Manifestations of the serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia; with possible rapid fluctuations of vital signs), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyper-reflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Fatal outcome of serotonin syndrome has been reported, including in patients who had been treated with Tranylcypromine Amdipharm. In some cases of an interaction between Tranylcypromine Amdipharm and SSRIs or SNRIs, the features of the syndrome resembled neuroleptic malignant syndrome.
The concomitant use, or use in rapid succession, of Tranylcypromine Amdipharm with other serotonergic drugs is contraindicated. However, there may be circumstances when treatment with other serotonergic substances (such as linezolid or intravenous methylene blue) is necessary and cannot be delayed. In such cases, Tranylcypromine Amdipharm must be discontinued as soon as possible before initiating treatment with the other agent.
Treatment with Tranylcypromine Amdipharm and any concomitant serotonergic agents should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.
Activation Of Mania Or Hypomania
In patients with bipolar disorder, treating a depressive episode with Tranylcypromine Amdipharm or another antidepressant may precipitate a mixed/manic episode. Prior to initiating treatment with Tranylcypromine Amdipharm, screen patients for any personal or family history of bipolar disorder, mania, or hypomania.
Hypotension
Hypotension, including postural hypotension, has been observed during therapy with Tranylcypromine Amdipharm. At doses above 30 mg daily, postural hypotension is a major adverse reaction and may result in syncope. Symptoms of postural hypotension are seen most commonly, but not exclusively, in patients with pre-existing hypertension. Blood pressure usually returns rapidly to pretreatment levels upon discontinuation of Tranylcypromine Amdipharm.
Dosage increases should be made more gradually in patients with a tendency toward hypotension and/or postural hypotension (e.g., elderly patients). Such patients should be closely observed for postural changes in blood pressure throughout treatment. Also, when Tranylcypromine Amdipharm is used concomitantly with other agents known to cause hypotension, the possibility of additive hypotensive effects should be considered. Postural hypotension may be relieved by having patients lie down until blood pressure returns to normal.
Hypotension And Hypertension During Anesthesia And Perioperative Care
It is recommended that Tranylcypromine Amdipharm be discontinued at least 10 days prior to elective surgery. If this is not possible, for general anesthesia, regional and local anesthesia, and perioperative care avoid the use of agents that are contraindicated for concomitant use with Tranylcypromine Amdipharm. Carefully consider the risk of agents and techniques that increase the risk for hypotension (e.g., epidural or spinal anesthesia) or other adverse reactions to Tranylcypromine Amdipharm (e.g., hypertension associated with the use of vasoconstrictors in local anesthetics).
Need For Emergency Treatment With Contraindicated Drugs
If in the absence of therapeutic alternatives emergency treatment with a contraindicated product (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue Tranylcypromine Amdipharm as soon as possible before initiating treatment with the other product and monitor closely for adverse reactions.
Discontinuation Syndrome
Abrupt discontinuation or dosage reduction of Tranylcypromine Amdipharm has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy.
There have been spontaneous reports of adverse reactions occurring upon discontinuation of MAOIs, particularly when abrupt, including dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these reactions are generally self-limiting, there have been reports of prolonged discontinuation symptoms.
Patients should be monitored for these symptoms when discontinuing treatment with Tranylcypromine Amdipharm. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible.
Risk Of Clinically Significant Adverse Reactions Due To Persistence Of MAO Inhibition After Discontinuation
Although excretion of Tranylcypromine Amdipharm is rapid, inhibition of MAO may persist up to 10 days following discontinuation. This should be taken into account when considering the use of potentially interacting substances or the consumption of tyramine-rich food or beverages , or when interpreting adverse reactions observed after discontinuation of Tranylcypromine Amdipharm. Care should be taken to differentiate symptoms of persistent MAO inhibition from withdrawal symptoms.
Hepatotoxicity
Hepatitis and elevated aminotransferases have been reported in association with Tranylcypromine Amdipharm administration. Patients should be monitored accordingly. Tranylcypromine Amdipharm should be discontinued in patients who develop signs and symptoms of hepatotoxicity.
Sedation has occurred in Tranylcypromine Amdipharm-treated patients with cirrhosis. Patients with cirrhosis receiving Tranylcypromine Amdipharm should be monitored for possible increased risks of central nervous system adverse reactions, such as excessive drowsiness.
Seizures
Seizures have been reported with Tranylcypromine Amdipharm withdrawal after abuse, and with overdose. Patients at risk for seizures should be monitored accordingly.
Hypoglycemia In Diabetic Patients
Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. Monitor blood glucose in patients receiving both Tranylcypromine Amdipharm and blood-glucose-lowering agents. A reduction of the dosage of such agents may be necessary
Aggravation Of Coexisting Symptoms Of Depression
Tranylcypromine Amdipharm may aggravate coexisting symptoms in depression, such as anxiety and agitation.
Adverse Effects On The Ability To Drive And Operate Machinery
Some Tranylcypromine Amdipharm adverse reactions (e.g., hypotension, faintness, drowsiness, confusion, disorientation) can impair a patient's ability to operate machinery or use an automobile. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Tranylcypromine Amdipharm therapy does not impair their ability to engage in such activities.
Patient Counseling Information
Advise the patient to read FDA-approved patient labeling (Medication Guide).
Suicidal Thoughts And Behaviors
Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during treatment and when the dosage is adjusted up or down.
Hypertensive Crisis
Advise the patient on possible symptoms and instruct the patient to seek immediate medical attention if related signs or symptoms are present
Serotonin Syndrome
Advise the patient on possible symptoms, and explain the potentially fatal nature of serotonin syndrome and that it may result from an interaction with other serotonergic drugs. Instruct the patient to seek immediate medical attention if related signs or symptoms are present
Interaction With Other Drugs And Dietary Supplements
- Warn the patient not to take concomitant medications, whether prescription or over-the-counter drugs, or dietary supplements without prior consultation with a health care provider able to provide advice on the potential for interactions.
- Explain to the patient that some other drugs may require a medication-free interval even after discontinuation of Tranylcypromine Amdipharm.
- Advise the patient to inform other physicians, pharmacists, and dentists about the treatment with Tranylcypromine Amdipharm.
Interaction With Foods And Beverages
- Warn the patient to avoid tyramine-rich foods and beverages.
- Advise the patient to avoid eating foods if storage conditions or freshness is unknown and to be cautious of foods of unknown age or composition even if refrigerated.
Hypotension
Advise the patient to report any symptoms of hypotension in the initial phase of treatment to the healthcare provider, because occurrence of such symptoms may require discontinuation.
Withdrawal Symptoms
Warn the patient not to stop Tranylcypromine Amdipharm treatment abruptly, as withdrawal symptoms may occur and that the effect of Tranylcypromine Amdipharm may continue even after discontinuation.
Aggravation Of Coexisting Symptoms Of Depression
Inform the patient that Tranylcypromine Amdipharm may aggravate coexisting symptoms in depression, such as anxiety and agitation and instruct them to contact their healthcare provider if they experience such symptoms.
Effects On Ability To Drive Or Use Machinery
- Warn the patient about the possible adverse reactions that can impair the performance of potentially hazardous tasks such as driving a car or operating machinery.
- Tell the patient not to operate hazardous machinery and automobiles until they are reasonably certain that their ability to engage in such activities is not impaired.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment Of Fertility
No carcinogenesis, mutagenesis, or fertility impairment studies were conducted.
Use In Specific Populations
Pregnancy
Risk Summary
There are limited published reports of placental infarction and congenital anomalies in association with use of Tranylcypromine Amdipharm during pregnancy; however, these reports may not adequately inform the presence or absence of drug-associated risk with the use of Tranylcypromine Amdipharm during pregnancy. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Animal embryo-fetal development studies were not conducted with tranylcypromine; however, published animal reproduction studies report placental transfer of tranylcypromine in rats and a dose-dependent decrease in uterine blood flow in pregnant sheep. Advise pregnant women of the potential risk to a fetus.
Clinical Considerations
Labor Or Delivery
During labor and delivery, the potential for interactions between Tranylcypromine Amdipharm and drugs or procedures (e.g., epidural anesthesia) should be taken into account in women who have received Tranylcypromine Amdipharm.
Lactation
Risk Summary
Tranylcypromine is present in human milk. There is no available information on the effects of tranylcypromine on milk production. There is no available information on the effects of tranylcypromine on a breastfed child; however, because of the potential for serious adverse reactions in a breastfed infant, advise nursing women to discontinue breastfeeding during treatment with Tranylcypromine Amdipharm.
Pediatric Use
Safety and effectiveness of Tranylcypromine Amdipharm in the pediatric population have not been established. All risks associated with the use of Tranylcypromine Amdipharm, including the risk of suicidal thoughts and behavior, apply to adults and pediatric patients.
Geriatric Use
Older patients may be at greater risk of postural hypotension and other serious adverse reactions. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Die folgenden Nebenwirkungen werden in anderen Abschnitten ausführlicher beschrieben:
- Selbstmordgedanken und -verhalten
- Hypertensive Krise und Bluthochdruck
- Serotonin-Syndrom
- Aktivierung von Manie / Hypomanie
- Hypotonie
- Hypotonie und Bluthochdruck während der Anästhesie und perioperativen Versorgung
- Abbruchsyndrom
- Persistenz der MAO-Hemmung nach Absetzen
- Hepatotoxizität
- Anfälle
- Hypoglykämie bei Diabetikern
- Verschärfung koexistierender Depressionssymptome
- Unerwünschte Auswirkungen auf die Fähigkeit, Maschinen zu fahren und zu bedienen
Da klinische Studien unter sehr unterschiedlichen Bedingungen durchgeführt werden, können die in den klinischen Studien eines Arzneimittels beobachteten Nebenwirkungen nicht direkt mit den Raten in den klinischen Studien eines anderen Arzneimittels verglichen werden und spiegeln möglicherweise nicht die in der Praxis beobachteten Raten wider.
Basierend auf Daten aus klinischen Studien waren die häufigsten Nebenwirkungen von Tranylcypromin Mundtrockenheit, Schwindel, Schlaflosigkeit, Sedierung und Kopfschmerzen (> 30%) sowie Überanstrengung, Verstopfung, Sehstörungen und Zittern (> 10%).
Die folgenden Nebenwirkungen wurden in klinischen Studien oder während der Anwendung von Tranylcypromin Amdipharm nach der Zulassung festgestellt:
Störungen des Blut- und Lymphsystems: Agranulozytose, Leukopenie, Thrombozytopenie, Anämie
Endokrine Störungen: beeinträchtigte Wasserausscheidung, die mit dem Syndrom der unangemessenen Sekretion von antidiuretischem Hormon (SIADH) vereinbar ist
Stoffwechsel- und Ernährungsstörungen: signifikante Magersucht, Gewichtszunahme
Psychiatrische Störungen: übermäßige Stimulation / Überanstrengung, manische Symptome / Hypomanie, Unruhe, Schlaflosigkeit, Angst, Verwirrung, Orientierungslosigkeit, Verlust der Libido
Störungen des Nervensystems: Schwindel, Unruhe / Akathisie, Akinesie, Ataxie, myoklonische Idioten, Zittern, Hyperreflexie, Muskelkrampf, Parästhesie, Taubheitsgefühl, Gedächtnisverlust, Beruhigung, Schläfrigkeit, Dysgeusie, Kopfschmerzen (ohne Blutdruckerhöhung)
Augenerkrankungen: verschwommenes Sehen, Nystagmus
Ohren- und Labyrinthstörungen: Tinnitus
Herzerkrankungen: Tachykardie, Herzklopfen
Gefäßerkrankungen: hypertensive Krise, Bluthochdruck, Hypotonie (einschließlich posturaler Hypotonie mit Synkope)
Magen-Darm-Erkrankungen: Durchfall, Verstopfung, Übelkeit, Bauchschmerzen, Mundtrockenheit, Risse im Mundwinkel
Hepatobiliäre Störungen: Hepatitis, erhöhte Aminotransferasen
Haut- und Unterhautstörungen: lokalisierte Sklerodermie, Aufflammen von zystischer Akne, Urtikaria, Hautausschlag, Alopezie, Schwitzen
Nieren- und Harnwegserkrankungen: Harnverhaltung, Harninkontinenz, Harnfrequenz
Störungen des Fortpflanzungssystems und der Brust: Impotenz, verzögerte Ejakulation
Allgemeine Störungen und Bedingungen am Verabreichungsort: Ödeme, Schüttelfrost, Schwäche, Müdigkeit / Lethargie
Überdosierungssymptome, Anzeichen und Laboranomalien
Eine Überdosierung von Tranylcypromin Amdipharm kann die Nebenwirkungen verursachen, die im Allgemeinen mit der Verabreichung von Tranylcypromin Amdipharm verbunden sind. Diese Reaktionen können jedoch schwerwiegender sein, einschließlich tödlicher Reaktionen. Zu den bei Überdosierung von Tranylcypromine Amdipharm und / oder anderen MAOs gemeldeten Effekten gehören:
- Schlaflosigkeit, Unruhe und Angstzustände, die in schweren Fällen zu Unruhe, geistiger Verwirrung und Inkohärenz führen; Delir; Anfälle
- Hypotonie, Schwindel, Schwäche und Schläfrigkeit, die in schweren Fällen zu extremem Schwindel und Schock führen
- Hypertonie mit starken Kopfschmerzen und anderen Symptomen / Komplikationen
- Zucken oder Myoklonfibrillation von Skelettmuskeln mit Hyperpyrexie, manchmal zu allgemeiner Steifigkeit und Koma
Überdosierungsmanagement
Es gibt keine spezifischen Gegenmittel für Tranylcypromine Amdipharm. Aktuelle Informationen zur Behandlung von Vergiftungen oder Überdosierungen erhalten Sie von einem Giftnotrufzentrum unter 1-800-222-1222.
Ein plötzlicher Entzug von Tranylcypromin Amdipharm nach Überdosierung kann Entzugssymptome, einschließlich Delir, auslösen.
Das medizinische Management sollte normalerweise aus allgemeinen unterstützenden Maßnahmen, einer genauen Beobachtung der Vitalfunktionen und Schritten bestehen, um spezifischen Manifestationen entgegenzuwirken, sobald sie auftreten. Die toxischen Wirkungen von Tranylcypromin Amdipharm können nach der letzten Dosis des Arzneimittels verzögert oder verlängert werden. Daher sollte der Patient mindestens 1 Woche lang genau beobachtet werden.
Daten zur Dialyzabilität von Tranylcypromin fehlen.